Search results for "Treatment experienced"

showing 4 items of 4 documents

Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort.

2021

Background In patients treated for HCV infection, potential drug–drug interactions (DDIs) can occur among direct-acting antiviral drugs (DAAs) and comedications used. The real-life effectiveness and safety of elbasvir/grazoprevir (ELB/GZR) among co-medicated HCV patients was evaluated. Methods We prospectively evaluated consecutive patients from 15 clinical centres participating in PITER who were treated with ELB/GZR and had been followed for at least 12 weeks after treatment. Data were prospectively collected on the use of comedications (including discontinuation, dose modification and addition of drugs) and potential DDIs with DAAs. Results Of the 356 patients with at least 12-week post-t…

Male030312 virologycombination therapytreatment experienced patientsDrug Combinationchronic hepatitis C drug drug interactions virus genotype 1 treatment experienced patients pump inhibitor use combination therapy treatment naive liver fibrosisgrazoprevir elbasvir80 and overAge FactorPharmacology (medical)Drug InteractionsProspective StudiesChronicProspective cohort studyliver fibrosisAged 80 and over0303 health sciencesAge FactorsImidazolesMiddle AgedHepatitis CDrug CombinationsInfectious DiseasesTreatment OutcomeDrug InteractionGrazoprevirCohortdrug drug interactionsFemalepump inhibitor useHumanmedicine.drugmedicine.medical_specialtyElbasvirQuinoxalinetreatment naiveelbasvirAntiviral AgentsNO03 medical and health sciencesInternal medicineQuinoxalinesmedicinechronic hepatitis CElbasvir GrazoprevirHumansImidazoleAgedBenzofuransAntiviral AgentPharmacology...business.industrygrazoprevirCarbamazepineHepatitis C Chronicmedicine.diseaseComorbidityDiscontinuationBenzofuranAge Factors; Aged; Aged 80 and over; Antiviral Agents; Benzofurans; Drug Combinations; Drug Interactions; Female; Hepatitis C Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Treatment Outcomebusinessvirus genotype 1Antiviral therapy
researchProduct

Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey

2014

S. Bruno1, S. Bollani1, A.L. Zignego2, V. Calvaruso3, C. Magni4, S. Landonio4, M. Rizzetto5, A. Ciancio5, A. Mangia6, V. Piazzolla6, M. Caremani7, S. Piovesan8, L. Cavalletto9, S. Babudieri9, A. Moretti 10, C. Colletta11, M. Massari12, S. Fangazio13, F. Mazzotta14, L. Muratori15, A.E. Colombo16, M. Zuin17, A. Traverso18, T. Santantonio19, F. Farina20, E. Marchionne21, G. Serviddio22, M. Russello23, A. Licata24, A. Craxi3, V. Di Marco3 1 Internal Medicine, AO Fatebenefratelli e Oftalmico, Milano, Italy 2 Internal Medicine, Universita di Firenze, Italy 3 Gastroenterology, Universita di Palermo, Italy 4 Infectiuos Diseases, Ospedale Sacco, Milano, Italy 5 Gastroenterology, Universita di Torino…

medicine.medical_specialtyHepatologybusiness.industryInfectious disease (medical specialty)Family medicineGastroenterologymedicinebusinessTreatment experiencedAdvanced fibrosisDigestive and Liver Disease
researchProduct

The Italian ENTAS cohort study: Entecavir effectiveness in naïve and treatment experienced patients with chronic hepatitis B

2015

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryInternal medicineGastroenterologyMedicineEntecavirbusinessTreatment experiencedmedicine.drugCohort studyDigestive and Liver Disease
researchProduct

The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer

2019

There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2Data of 154 patients were retrospectively collected at 14 Italian institutions through a specifically designed database.Median overall survival (OS) was 24.5 months. Patients receiving surgery/stereotactic radiosurgery experienced longer OS compared to those receiving whole-brain radiotherapy or no treatment (33.5 vs. 11.4 months; hazard ratio = 0.34; 95% confidence interval, 0.22-0.52; P .001). Interestingly, whole-brain radiotherapy did not improve OS compared to no treatment (11.4 vs. 9.8 months; hazard ratio = 0.99; 95% confidence interval, 0.62-1.62; P = .99). HER2-targeted …

Adult0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentSocio-culturaleBreast NeoplasmsLapatinibTreatment experiencedRadiosurgerySRS03 medical and health sciences0302 clinical medicineBreast cancerTrastuzumabInternal medicineHER2 Positive Breast CancerBiomarkers TumormedicineHumansAgedRetrospective Studiesbusiness.industryLapatinibTrastuzumabMiddle AgedWBRTPrognosismedicine.diseaseCombined Modality TherapyConfidence intervalSurvival RateRadiation therapyLapatinib SRS Surgery Trastuzumab WBRT030104 developmental biologyReceptors EstrogenOncology030220 oncology & carcinogenesisLapatinib; SRS; Surgery; Trastuzumab; WBRTSurgeryFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studiesmedicine.drugClinical Breast Cancer
researchProduct